热门资讯> 正文

AVROBIO GAAP EPS of -$0.84 beats by $0.55

2025-03-21 04:45

AVROBIO(AVRO) 0
Tectonic Therapeutic Inc(TECX) 0

AVROBIO press release (NASDAQ:TECX): Q4 GAAP EPS of -$0.84 beats by $0.55.
As of December 31, 2024, cash and cash equivalents were $141.2 million, compared to $159.1 million as of September 30, 2024. Tectonic anticipates that, based on current operating assumptions, its current cash and cash equivalents will provide a cash runway into Q4’28, including through key Phase 1b and Phase 2 readouts for TX45, and the progression of the HHT program into clinical development.

More on AVROBIO

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic announces ~$185M capital raise
Tectonic jumps on positive data from early-stage trial for lead asset

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。